<span item_type="fundamental" item_id="36d62fcb6629ca6ef2bd41ed18279d8f" counter_id="ST/US/GOVX" env="prod"></span><span item_type="announcement" item_id="637883448411555329" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 2.489 M.</p><p>EPS: As of FY2025, the actual value is USD -22.4.</p><p></p><h4>Financial Results for the Year Ended December 31, 2025, Compared to 2024</h4><h4>Revenue</h4><p>Revenue from government contracts for GeoVax Labs, Inc. decreased to $2.5 million in 2025 from $4.0 million in 2024, primarily due to the termination of the BARDA/RRPV contract <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>.</p><h4>Net Loss</h4><p>GeoVax Labs, Inc. reported a net loss of - $21.5 million, or - $22.40 per share, for 2025, an improvement from a net loss of - $25.0 million, or - $120.46 per share, in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>.</p><h4>Operating Expenses</h4><p>Research and development (R&amp;D) expenses were $18.1 million in 2025, down from $23.7 million in 2024, mainly due to discontinued costs from the BARDA/RRPV contract termination and lower costs for GEO-CM04S1 clinical trials and manufacturing <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>. General and administrative (G&amp;A) expenses increased to $6.0 million in 2025 from $5.4 million in 2024, driven by higher personnel costs, investor relations consulting, other programmatic expenses, patent costs, and stock-based compensation <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>. Loss from operations was - $21.6 million in 2025, compared to - $25.1 million in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>.</p><h4>Cash Position</h4><p>Cash and cash equivalents were $3.1 million as of December 31, 2025, a decrease from $5.5 million as of December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>.</p><h4>Operational Metrics and Program Updates</h4><p>GeoVax Labs, Inc. plans to initiate a pivotal Phase 3 clinical trial for GEO-MVA (Mpox/Smallpox Vaccine) in the second half of 2026, supported by a streamlined development pathway from the European Medicines Agency (EMA) <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>. The company completed cGMP manufacturing and fill-finish of clinical-grade GEO-MVA <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>. For GEO-CM04S1 (COVID-19 Vaccine), data readouts from multiple Phase 2 clinical trials for immunocompromised populations are anticipated in 2026, with interim findings from the CLL study showing superior immune responses <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>. GeoVax Labs, Inc. completed Phase <sup>1</sup>⁄<sub>2</sub> clinical evaluation for Gedeptin® (Oncology) in advanced head and neck cancer and entered an exclusive license agreement with Emory University for combination use, with a Phase 2 trial planned for 2027 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>.</p><h4>Outlook / Guidance</h4><p>GeoVax Labs, Inc. prioritizes executing key GEO-MVA clinical and regulatory milestones and strengthening strategic partnerships <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>. The company anticipates initiating the planned Phase 3 immuno-bridging study for GEO-MVA in the second half of 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>. Additionally, data readouts for GEO-CM04S1 are expected in 2026, and a Phase 2 trial for Gedeptin® is planned for 2027 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm"></span>.</p>

GeoVax Labs | 8-K: FY2025 Revenue: USD 2.489 M